Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 34

1.

Nanoparticles versus Dendritic Cells as Vehicles to Deliver mRNA Encoding Multiple Epitopes for Immunotherapy.

Firdessa-Fite R, Creusot RJ.

Mol Ther Methods Clin Dev. 2019 Nov 11;16:50-62. doi: 10.1016/j.omtm.2019.10.015. eCollection 2020 Mar 13.

2.

Phenotypic alterations in pancreatic lymph node stromal cells from human donors with type 1 diabetes and NOD mice.

Postigo-Fernandez J, Farber DL, Creusot RJ.

Diabetologia. 2019 Nov;62(11):2040-2051. doi: 10.1007/s00125-019-04984-w. Epub 2019 Sep 5.

PMID:
31486854
3.

Soluble Antigen Arrays Displaying Mimotopes Direct the Response of Diabetogenic T Cells.

Leon MA, Firdessa-Fite R, Ruffalo JK, Pickens CJ, Sestak JO, Creusot RJ, Berkland C.

ACS Chem Biol. 2019 Jul 19;14(7):1436-1448. doi: 10.1021/acschembio.9b00090. Epub 2019 Jul 1.

PMID:
31260253
4.

Transgenic substitution with Greater Amberjack Seriola dumerili fish insulin 2 in NOD mice reduces beta cell immunogenicity.

Foo KS, Skowronski AA, Baum D, Firdessa-Fite R, Thams S, Shang L, Creusot RJ, LeDuc CA, Egli D, Leibel RL.

Sci Rep. 2019 Mar 21;9(1):4965. doi: 10.1038/s41598-019-40768-3.

5.

Humanized Mice Reveal New Insights Into the Thymic Selection of Human Autoreactive CD8+ T Cells.

Li Y, Teteloshvili N, Tan S, Rao S, Han A, Yang YG, Creusot RJ.

Front Immunol. 2019 Feb 4;10:63. doi: 10.3389/fimmu.2019.00063. eCollection 2019.

6.

A multi-epitope DNA vaccine enables a broad engagement of diabetogenic T cells for tolerance in Type 1 diabetes.

Postigo-Fernandez J, Creusot RJ.

J Autoimmun. 2019 Mar;98:13-23. doi: 10.1016/j.jaut.2018.11.003. Epub 2018 Nov 17.

PMID:
30454875
7.

Altered Function of Antigen-Presenting Cells in Type 1 Diabetes: A Challenge for Antigen-Specific Immunotherapy?

Creusot RJ, Postigo-Fernandez J, Teteloshvili N.

Diabetes. 2018 Aug;67(8):1481-1494. doi: 10.2337/db17-1564. Review.

8.

PPARγ deacetylation dissociates thiazolidinedione's metabolic benefits from its adverse effects.

Kraakman MJ, Liu Q, Postigo-Fernandez J, Ji R, Kon N, Larrea D, Namwanje M, Fan L, Chan M, Area-Gomez E, Fu W, Creusot RJ, Qiang L.

J Clin Invest. 2018 Jun 1;128(6):2600-2612. doi: 10.1172/JCI98709. Epub 2018 May 14.

9.

Efficient Presentation of Multiple Endogenous Epitopes to Both CD4+ and CD8+ Diabetogenic T Cells for Tolerance.

Dastagir SR, Postigo-Fernandez J, Xu C, Stoeckle JH, Firdessa-Fite R, Creusot RJ.

Mol Ther Methods Clin Dev. 2016 Dec 24;4:27-38. doi: 10.1016/j.omtm.2016.12.002. eCollection 2017 Mar 17.

10.

Concise Review: Cell-Based Therapies and Other Non-Traditional Approaches for Type 1 Diabetes.

Creusot RJ, Battaglia M, Roncarolo MG, Fathman CG.

Stem Cells. 2016 Apr;34(4):809-19. doi: 10.1002/stem.2290. Epub 2016 Feb 9. Review.

11.

Toward beta cell replacement for diabetes.

Johannesson B, Sui L, Freytes DO, Creusot RJ, Egli D.

EMBO J. 2015 Apr 1;34(7):841-55. doi: 10.15252/embj.201490685. Epub 2015 Mar 1. Review.

12.

Inflammation and hyperglycemia mediate Deaf1 splicing in the pancreatic lymph nodes via distinct pathways during type 1 diabetes.

Yip L, Fuhlbrigge R, Taylor C, Creusot RJ, Nishikawa-Matsumura T, Whiting CC, Schartner JM, Akter R, von Herrath M, Fathman CG.

Diabetes. 2015 Feb;64(2):604-17. doi: 10.2337/db14-0803. Epub 2014 Sep 3.

13.

It's time to bring dendritic cell therapy to type 1 diabetes.

Creusot RJ, Giannoukakis N, Trucco M, Clare-Salzler MJ, Fathman CG.

Diabetes. 2014 Jan;63(1):20-30. doi: 10.2337/db13-0886. Review. No abstract available.

14.

[Superkines: cytokines displaying better targeted functions].

Creusot RJ, Moraga I.

Med Sci (Paris). 2013 Apr;29(4):345-9. doi: 10.1051/medsci/2013294004. Epub 2013 Apr 26. French. No abstract available.

15.

Initiating type I diabetes: new suspects in the lineup.

Creusot RJ.

Nat Med. 2013 Jan;19(1):18-20. doi: 10.1038/nm.3044. No abstract available.

PMID:
23296002
16.

Redirecting cell-type specific cytokine responses with engineered interleukin-4 superkines.

Junttila IS, Creusot RJ, Moraga I, Bates DL, Wong MT, Alonso MN, Suhoski MM, Lupardus P, Meier-Schellersheim M, Engleman EG, Utz PJ, Fathman CG, Paul WE, Garcia KC.

Nat Chem Biol. 2012 Dec;8(12):990-8. doi: 10.1038/nchembio.1096. Epub 2012 Oct 28.

17.

Reduced DEAF1 function during type 1 diabetes inhibits translation in lymph node stromal cells by suppressing Eif4g3.

Yip L, Creusot RJ, Pager CT, Sarnow P, Fathman CG.

J Mol Cell Biol. 2013 Apr;5(2):99-110. doi: 10.1093/jmcb/mjs052. Epub 2012 Aug 24.

18.

NF-κB in DCs: it takes effort to be immature.

Creusot RJ.

Nat Med. 2011 Dec 6;17(12):1554-6. doi: 10.1038/nm.2586. No abstract available.

PMID:
22146457
19.

A short pulse of IL-4 delivered by DCs electroporated with modified mRNA can both prevent and treat autoimmune diabetes in NOD mice.

Creusot RJ, Chang P, Healey DG, Tcherepanova IY, Nicolette CA, Fathman CG.

Mol Ther. 2010 Dec;18(12):2112-20. doi: 10.1038/mt.2010.146. Epub 2010 Jul 13.

20.

Deaf1 isoforms control the expression of genes encoding peripheral tissue antigens in the pancreatic lymph nodes during type 1 diabetes.

Yip L, Su L, Sheng D, Chang P, Atkinson M, Czesak M, Albert PR, Collier AR, Turley SJ, Fathman CG, Creusot RJ.

Nat Immunol. 2009 Sep;10(9):1026-33. doi: 10.1038/ni.1773. Epub 2009 Aug 9.

21.

Lymphoid-tissue-specific homing of bone-marrow-derived dendritic cells.

Creusot RJ, Yaghoubi SS, Chang P, Chia J, Contag CH, Gambhir SS, Fathman CG.

Blood. 2009 Jun 25;113(26):6638-47. doi: 10.1182/blood-2009-02-204321. Epub 2009 Apr 10.

22.

TSG-6 protein expression in the pancreatic islets of NOD mice.

Kvezereli M, Michie SA, Yu T, Creusot RJ, Fontaine MJ.

J Mol Histol. 2008 Dec;39(6):585-93. doi: 10.1007/s10735-008-9199-5. Epub 2008 Nov 1.

PMID:
18979174
23.

Tissue- and age-specific changes in gene expression during disease induction and progression in NOD mice.

Kodama K, Butte AJ, Creusot RJ, Su L, Sheng D, Hartnett M, Iwai H, Soares LR, Fathman CG.

Clin Immunol. 2008 Nov;129(2):195-201. doi: 10.1016/j.clim.2008.07.028. Epub 2008 Sep 17.

24.

Tissue-targeted therapy of autoimmune diabetes using dendritic cells transduced to express IL-4 in NOD mice.

Creusot RJ, Yaghoubi SS, Kodama K, Dang DN, Dang VH, Breckpot K, Thielemans K, Gambhir SS, Fathman CG.

Clin Immunol. 2008 May;127(2):176-87. doi: 10.1016/j.clim.2007.12.009. Epub 2008 Mar 12.

25.

Multimodality imaging of T-cell hybridoma trafficking in collagen-induced arthritic mice: image-based estimation of the number of cells accumulating in mouse paws.

Yaghoubi SS, Creusot RJ, Ray P, Fathman CG, Gambhir SS.

J Biomed Opt. 2007 Nov-Dec;12(6):064025. doi: 10.1117/1.2821415.

26.

Targeted gene therapy of autoimmune diseases: advances and prospects.

Creusot RJ, Fathman CG, Müller-Ladner U, Tarner IH.

Expert Rev Clin Immunol. 2005 Sep;1(3):385-404. doi: 10.1586/1744666X.1.3.385.

PMID:
20476990
27.

IFN-gamma gene expression is controlled by the architectural transcription factor HMGA1.

Chau KY, Keane-Myers AM, Fedele M, Ikeda Y, Creusot RJ, Menozzi L, Cousins DJ, Manfioletti G, Feigenbaum L, Fusco A, Ono SJ.

Int Immunol. 2005 Mar;17(3):297-306. Epub 2005 Feb 14.

PMID:
15710911
28.

Murine CD4+CD25+ regulatory T cells fail to undergo chromatin remodeling across the proximal promoter region of the IL-2 gene.

Su L, Creusot RJ, Gallo EM, Chan SM, Utz PJ, Fathman CG, Ermann J.

J Immunol. 2004 Oct 15;173(8):4994-5001.

29.
30.

How DCs control cross-regulation between lymphocytes.

Creusot RJ, Mitchison NA.

Trends Immunol. 2004 Mar;25(3):126-31. Review. No abstract available.

PMID:
15036039
31.

Local cooperation dominates over competition between CD4+ T cells of different antigen/MHC specificity.

Creusot RJ, Thomsen LL, Tite JP, Chain BM.

J Immunol. 2003 Jul 1;171(1):240-6.

32.

Instruction of naive CD4+ T cells by polarized CD4+ T cells within dendritic cell clusters.

Creusot RJ, Biswas JS, Thomsen LL, Tite JP, Mitchison NA, Chain BM.

Eur J Immunol. 2003 Jun;33(6):1686-96.

33.

The immunological synapse.

Creusot RJ, Mitchison NA, Terazzini NM.

Mol Immunol. 2002 May;38(12-13):997-1002. Review.

PMID:
12009579
34.

Early commitment of adoptively transferred CD4+ T cells following particle-mediated DNA vaccination: implications for the study of immunomodulation.

Creusot RJ, Thomsen LL, van Wely CA, Topley P, Tite JP, Chain BM.

Vaccine. 2001 Feb 8;19(13-14):1678-87.

PMID:
11166891

Supplemental Content

Loading ...
Support Center